Ken Griffin Edgewise Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Edgewise Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 70,000 shares of EWTX stock, worth $2.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

70,000

Previous 10,900 542.2%

Holding current value

$2.25 Million

Previous $196,000 853.06%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$15.88 - $29.5 $28.8 Million - $53.4 Million	-1,810,925 Reduced 77.09%	538,249 $14.4 Million
Q2 2024 Aug 14, 2024	SELL	$15.08 - $21.23 $5.58 Million - $7.86 Million	-370,117 Reduced 13.61%	2,349,174 $42.3 Million
Q1 2024 May 15, 2024	BUY	$9.25 - $19.97 $1.23 Million - $2.66 Million	133,361 Added 5.16%	2,719,291 $49.6 Million
Q4 2023 Feb 14, 2024	SELL	$5.51 - $12.1 $1 Million - $2.2 Million	-181,506 Reduced 6.56%	2,585,930 $28.3 Million
Q3 2023 Nov 14, 2023	BUY	$5.73 - $7.69 $529,715 - $710,909	92,446 Added 3.46%	2,767,436 $15.9 Million
Q2 2023 Aug 14, 2023	SELL	$5.71 - $10.29 $533,588 - $961,579	-93,448 Reduced 3.38%	2,674,990 $20.7 Million
Q1 2023 May 15, 2023	SELL	$6.66 - $11.33 $520,019 - $884,657	-78,081 Reduced 2.74%	2,768,438 $18.5 Million
Q4 2022 Feb 14, 2023	BUY	$7.58 - $11.08 $642,746 - $939,528	84,795 Added 3.07%	2,846,519 $25.4 Million
Q3 2022 Nov 14, 2022	BUY	$8.08 - $13.58 $1.81 Million - $3.04 Million	223,706 Added 8.81%	2,761,724 $27.2 Million

Others Institutions Holding EWTX

# of Institutions

191

Shares Held

100M

Call Options Held

2.17M

Put Options Held

410K

View Full List

About Edgewise Therapeutics, Inc.

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $2.03B
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

More about EWTX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account